After more than 5 years of ATDs use, the FT4 and total thyroxine (TT4) levels significantly declined in the pGD patients compared with those observed in the nGD patients (FT4: 21.00 pmol/L vs 34.60 pmol/L, P = 0.036; TT4: 12.35 pmol/L vs 20.64 pmol/L, P = 0.003), while there were no differences in other thyroid-associated parameters, including TSH, anti-thyroglobulin autoantibodies (TGAb), anti-thyroid microsomal autoantibodies (TMAb), and anti-thyroid stimulating hormone receptor autoantibodies (TRAb). The gene discussed is TSHR; the disease is thyroid gland disorder.